Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06672068 | A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC | not yet recruiting | Phase 2 | 60 | TYK Medicines, IncINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT06752408 | Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer(ANOTHER) | not yet recruiting | Phase 2 | 316 | Peking Union Medical College HospitalOTHER | 1 |
| Dec 30, 2024 |
| clinicaltrials |
| NCT06746870 | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 148 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT06738680 | PRedictive Value of Multiparametric Dynamic WB 18F-FDG-PET Imaging on a LAFOV System for FIRST-line Chemo-immunotherapy Efficacy in Advanced Non-small-cell Lung Cancer: PROFIL-1(PROFIL-1) | not yet recruiting | — | 120 | University Hospital, BrestOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06739421 | The Diagnostic Value of Bronchoscopic Needle-based Confocal Laser Endomicroscopy (nCLE) As a Real-time Detection Tool for Diagnosing Peripheral Lung Cancer: a Multi-centre Randomised Controlled Trial | not yet recruiting | N/A | 1,040 | China-Japan Friendship HospitalOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06704620 | Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 430 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06735508 | MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer | not yet recruiting | Early Phase 1 | 40 | Guangdong Provincial People's HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT06736561 | A Multicenter Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients. | not yet recruiting | — | 100 | Harbin Medical UniversityOTHER | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06719336 | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | not yet recruiting | Phase 3 | 182 | Anhui Shi, MDOTHER | 0 | Dec 5, 2024 | clinicaltrials |
| NCT06709274 | Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC(MOTION-NSCLC) | not yet recruiting | N/A | 342 | Guangdong Association of Clinical TrialsOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06694129 | Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC | not yet recruiting | — | 40 | National Cancer Center, ChinaOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT06690541 | Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC(COMLORLA) | not yet recruiting | — | 100 | Peking University Cancer Hospital & InstituteOTHER | 0 | Nov 15, 2024 | clinicaltrials |
| NCT06690671 | A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC | not yet recruiting | Phase 1 / Phase 2 | 30 | Shanghai Chest HospitalOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06685653 | Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients | not yet recruiting | Early Phase 1 | 65 | Nanjing Tianyinshan HospitalOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06672133 | Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC(RALLY) | not yet recruiting | Phase 3 | 524 | Jinming YuOTHER | 0 | Nov 5, 2024 | clinicaltrials |
| NCT06652555 | The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study | not yet recruiting | — | 100 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 22, 2024 | clinicaltrials |
| NCT06645743 | Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma | not yet recruiting | — | 1,100 | The Third Affiliated Hospital of Kunming Medical College.OTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06646770 | SEgmentectomy Versus Lobectomy in T1C Non-Small Cell Lung Cancer (SELTIC)(SELTIC) | not yet recruiting | N/A | 400 | Istanbul University - CerrahpasaOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06643910 | A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer | not yet recruiting | N/A | 12 | BioSyngen Pte LtdINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06644313 | Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 2 | 31 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06597513 | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | not yet recruiting | Phase 1 / Phase 2 | 10 | Zhou ChengzhiOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06634667 | Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI Resistance | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06618391 | Local Injection and Systemic Therapy in the Treatment of NSCLC. | not yet recruiting | Phase 2 | 84 | Henan Cancer HospitalOTHER_GOV | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06620796 | A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06620822 | Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial | not yet recruiting | Phase 2 | 296 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614231 | Neoajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectable Stage IIIA/N2 Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06614621 | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06607926 | Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC | not yet recruiting | N/A | 40 | Xuanwu Hospital, BeijingOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06537297 | Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases | not yet recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06497543 | Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic | not yet recruiting | Phase 2 | 80 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586801 | The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China | not yet recruiting | — | 800 | Shanghai East HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06591910 | Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer | not yet recruiting | — | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06594874 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | not yet recruiting | Phase 1 | 350 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06602661 | Reinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy | not yet recruiting | Phase 1 | 65 | Surrey Thoracic Surgery GroupOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06604351 | Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction(Example) | not yet recruiting | Phase 2 | 39 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06585059 | Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers | not yet recruiting | Phase 1 | 20 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06581380 | JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 394 | JenKem Technology Co., Ltd.INDUSTRY | 0 | Sep 3, 2024 | clinicaltrials |
| NCT06483009 | Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC | not yet recruiting | Phase 4 | 20 | Shanghai Chest HospitalOTHER | 0 | Aug 30, 2024 | clinicaltrials |
| NCT06580665 | Cryoablation with or Without Serplulimab in Treating Patients with Stage I-IIA Non-small Cell Lung Cancer | not yet recruiting | N/A | 134 | Shanghai Chest HospitalOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT06557096 | CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC | not yet recruiting | Early Phase 1 | 100 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 16, 2024 | clinicaltrials |
| NCT06554535 | Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Aug 15, 2024 | clinicaltrials |
| NCT06526624 | A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 406 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06502249 | Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) | not yet recruiting | — | 60 | Ain Shams UniversityOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06462105 | Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer | not yet recruiting | N/A | 60 | Zhou ChengzhiOTHER | 0 | Jun 28, 2024 | clinicaltrials |
| NCT06475755 | Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC | not yet recruiting | Phase 2 | 178 | Tang-Du HospitalOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06454890 | Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 1 / Phase 2 | 50 | Henan Cancer HospitalOTHER_GOV | 0 | Jun 12, 2024 | clinicaltrials |
| NCT06452433 | Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer. | not yet recruiting | Phase 2 | 91 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 11, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Dec 30, 2024source: clinicaltrials